Insight Molecular Diagnostics
IMDX
21 hedge funds and large institutions have $20.4M invested in Insight Molecular Diagnostics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.18% more ownership
Funds ownership: 53.42% → 53.6% (+0.18%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $21.1M → $20.4M (-$646K)
9% less funds holding
Funds holding: 23 → 21 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
FNY Investment Advisers
New York
|
+$59.7K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$35K |
| 3 |
BlackRock
New York
|
+$21.7K |
| 4 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$12.8K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$30.7K |
| 2 |
Morgan Stanley
New York
|
-$19.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.04K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$1.48K |
| 5 |
RAM
Riggs Asset Management
Dallas,
Pennsylvania
|
-$148 |
IMDX Hedge Fund Activity: Q3 2024 in Review
21 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q3 2024, worth a combined $20.4M — down 3.1% from $21.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IMDX and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was FNY Investment Advisers, adding an estimated $59.7K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $30.7K sold.
- 21 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q3 2024, down from 23 in Q2 2024.
- Funds reported $20.4M of Insight Molecular Diagnostics stock for Q3 2024, down 3.1% quarter-over-quarter.
- 2 funds opened new Insight Molecular Diagnostics positions in Q3 2024 and 4 closed out, a net change of -2 holders.
- The largest Insight Molecular Diagnostics buyer in Q3 2024 was FNY Investment Advisers, an estimated $59.7K added.
- The largest Insight Molecular Diagnostics seller in Q3 2024 was Renaissance Technologies, an estimated $30.7K sold.
Based on aggregated 13F filings for Q3 2024.